The estimated Net Worth of Ryan Martins is at least $823 Thousand dollars as of 4 April 2023. Mr. Martins owns over 8,721 units of 89bio Inc stock worth over $434,518 and over the last 5 years he sold ETNB stock worth over $388,773. In addition, he makes $0 as Chief Financial Officer at 89bio Inc.
Ryan has made over 7 trades of the 89bio Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 8,721 units of ETNB stock worth $130,379 on 4 April 2023.
The largest trade he's ever made was exercising 10,000 units of 89bio Inc stock on 19 April 2021 worth over $31,100. On average, Ryan trades about 1,491 units every 29 days since 2020. As of 4 April 2023 he still owns at least 53,578 units of 89bio Inc stock.
You can see the complete history of Mr. Martins stock trades at the bottom of the page.
Ryan Martins serves as Chief Financial Officer of the Company. Prior to joining our company, Mr. Martins was Chief Financial Officer at Revolution Medicines, Inc., from March 2018 to October 2018, where he was responsible for all aspects of the finance function including financial accounting, capital planning, audit, tax and investor relations. Before Revolution Medicines, Mr. Martins was Vice President and Head of Corporate Strategy and Investor Relations at Ultragenyx Pharmaceutical, Inc., from September 2015 to March 2018, where he was responsible for strategic planning, capital raising, investor relations and assisting business development. Prior to Ultragenyx, Mr. Martins spent nearly 10 years as a biotechnology analyst at Jefferies, Lazard, and Barclays/Lehman Brothers after holding operating roles at Chiron Corporation from 2001 to 2006.
Ryan Martins is 43, he's been the Chief Financial Officer of 89bio Inc since 2019. There are 15 older and 1 younger executives at 89bio Inc. The oldest executive at 89bio Inc is Michael Hayden, 68, who is the Independent Director.
Ryan's mailing address filed with the SEC is C/O 89BIO, INC., 142 SANSOME STREET, 2ND FLOOR, SAN FRANCISCO, CA, 94104.
Over the last 5 years, insiders at 89bio Inc have traded over $17,267,666 worth of 89bio Inc stock and bought 14,519,952 units worth $208,678,684 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ..., and Advisors Llc Orbi Med Capit.... On average, 89bio Inc executives and independent directors trade stock every 28 days with the average trade being worth of $2,197,340. The most recent stock trade was executed by Rohan Palekar on 1 April 2024, trading 52,718 units of ETNB stock currently worth $575,153.
89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.
89bio Inc executives and other stock owners filed with the SEC include: